Posted by Michael Wonder on 15 Dec 2022
PHARMAC consulting on two new medicines for lung cancer
16 December 2022 - PHARMAC has reached provisional agreements with two different suppliers to fund two medicines to treat New Zealanders with advanced non-small-cell lung cancer.
The medicines are pembrolizumab (Keytruda) and atezolizumab (Tecentriq).
